The Role of Platelets in Essential Hypertension

References

• Young W, Gofman J W, Tandy R. The quantitation of atherosclerosis II: quantitative aspects of the relationship of blood pressure and atherosclerosis. Am J Cardiol 1960; 6: 294–9
   PubMedGoogle Scholar
• Baker A B, Resch J A, Loewenson R B. Hypertension and cerebral atherosclerosis. Circulation 1969; 39: 701–10
   PubMedGoogle Scholar
• Sodeshima S, Kurozumi T, Tanaka K. Cerebral and aortic atherosclerosis in Hisayama Japan. Atherosclerosis 1980; 36: 117–26
   PubMedGoogle Scholar
• Mustard J F, Murphy E A, Rowsell H C. Platelets and atherosclerosis. J Atherosclerosis Res 1984; 4: 1–28
   Google Scholar
• Ross R, Glomset J A. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369–77; 420–5
   PubMed Web of Science ®Google Scholar
• Fred De Clerck. Review: blood platelets in human essential hypertension. Agents and Actions 1986; 18(516)563–80
   PubMedGoogle Scholar
• Islim I F, Beevers D G, Bareford D. The affect of antihypertensive drugs on in vivo platelet activity in essential hypertension. J Hypertens 1992; 10: 379–83
   PubMedGoogle Scholar
• Yamanishi J, Sano H, Saitu K. Plasma concentrations of platelet-specific proteins in different stages of essential hypertension: interactions between platelet aggregation blood lipids and age. Thromb Haemost 1985; 54: 539–43
   PubMed Web of Science ®Google Scholar
• Gomi T, Ikeda T, Yuhara M. Plasma betathromboglobulin to platelet function 4 ratios as indices of vascular complications in essential hypertension. J Hypertens 1988; 6: 389–92
   PubMedGoogle Scholar
• Mehta J, Mehta P. Platelet function in hypertension and the effect of therapy. Am J Cardiol 1981; 47: 331–4
   PubMed Web of Science ®Google Scholar
• Holmsen H. Platelet secretion. Hemostasis and thrombosis: basic principals and clinical practice, 2nd ed, R W Colman, J Hirsh, V J Marder. Lippincott, Philadelphia 1987; 606–17
   Google Scholar
• Rink T J, Hallam T J. What turns platelets on. Trends Biochem Sci 1984; 9: 215–9
   Web of Science ®Google Scholar
• Holmsen H. Platelet metabolism and activation. Sem Haematol 1985; 22: 219–40
   PubMed Web of Science ®Google Scholar
• Hutton R A. Normal haemostasis. Postgraduate haematology, 3rd ed, A V Hoffbrand, S M Lewis. Butterworth-Heinemann, Oxford 1989; 560–94
   Google Scholar
• Marcus A J. Platelets and their disorders. Disorders of haemostasis, 2nd ed, O D Ratnoff, C D Forbes. Saunders, Philadelphia 1991; 75–140
   Google Scholar
• Holmsen H, Karpantkin S. Metabolism of platelets. Haematology, 3rd ed, W Williams, E Bentler, A Erslev. McGraw-Hill, New York 1983; 1149–76
   Google Scholar
• Davies J A, McNicol G P. Haemostasis and thrombosis. Oxford textbook of medicine, D J Wealtherall, J GG Ledingham, D A Worrelll. Oxford University Press, Oxford 1984; 19: 112–19; 113
   Google Scholar
• Kitchens C S, Weiss L. Ultrastructural changes to endothelium associated with thrombocytopaenia. Blood 1975; 46: 567–78
   PubMed Web of Science ®Google Scholar
• Maca R D, Fry G L, Hoak J C. The effect of intact platelets on cultured endothelial cells. Thromb Res 1977; 11: 715–27
   PubMedGoogle Scholar
• Miyazono K, Tetsuro O, Ishibashi S. A platelet factor stimulating the proliferation of vascular endothelial cells. Partial purification and characterisation. Exp Cell Res 1985; 159: 487–94
   PubMedGoogle Scholar
• Moncada S, Gryglewski R J, Bunting S. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–5
   PubMed Web of Science ®Google Scholar
• Palmer R MJ, Ferriga A G, Moncada S. Release of nitric oxide accounts for the biological activity of endothelium derived relaxing factor. Nature 1987; 327: 524–6
   PubMed Web of Science ®Google Scholar
• Waldman S A, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987; 39: 163–96
   PubMed Web of Science ®Google Scholar
• Pearson J D, Gordon V L. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature 1979; 281: 384–6
   PubMed Web of Science ®Google Scholar
• Marcum J A, Rosenberg R D. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126: 365–72
   PubMed Web of Science ®Google Scholar
• Gregorious F K, Rand R W. Scanning electron microscopy of the common carotid artery. III. Heparin effect on platelets. Surgery 1976; 79: 583–9
   Google Scholar
• Santoro S A, Cunningham L W. Collagen-mediated platelet aggregation. Evidence for multivalent interactions of intermediate specificity between collagen and platelets. J Clin Invest 1977; 60: 1054–60
   PubMedGoogle Scholar
• Sussman I I, Rand J R. Subendothelial deposition of von Willebrand factor requires the presence of subendothelial cells. J Lab Clin Med 1982; 100: 526–32
   PubMedGoogle Scholar
• Santoro S A. Absorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 1981; 21: 689–93
   PubMedGoogle Scholar
• Turrito V T, Baumgartner H R. Platelet adhesion. Measurement of platelet function, L N Harker, T S Zimmerman. Churchill Livingstone, Edinburgh 1983; 46–63
   Google Scholar
• Plow E F, Ginsberg M H. Specific and saturable binding of plasma fibronectin to thrombin-stimulated platelets. J Biol Chem 1981; 256: 9477
   PubMed Web of Science ®Google Scholar
• Plow E F, Marguerie G A, Ginsberg M H. Fibronectin binding to thrombin-stimulated platelets: evidence for fibrinogen independent and dependent pathways. Blood 1985; 66: 26–32
   PubMedGoogle Scholar
• Girma J-P, Meyer D, Verweij C L. Structure-function relationship of human von Willebrand factor. Blood 1987; 70: 605–11
   PubMed Web of Science ®Google Scholar
• Davies J A, McNicol G P. Haemostasis and thrombosis. Oxford textbook of medicine, D J Weatherall, J GG Ledingham, D A Warrell. Oxford University Press, Oxford 1984; 19–114
   Google Scholar
• Ill C R, Engvall E, Ruoslahti E S. Adhesion of platelets to laminin in the absence of activation. J Cell Biol 1984; 99: 2140–5
   PubMedGoogle Scholar
• De Groot PhG, Ottehof-Rovers M, Dziadek M. Nidogen is present in the extracellular matrix of human endothelial cells and is involved in platelet adhesion to this matrix. Thromb Haemost 1985; 54: 231
   Google Scholar
• Erdos E G. Angiotensin I converting enzyme. Circ Res 1975; 36: 247–55
   PubMed Web of Science ®Google Scholar
• Studdy P R, Lapworth R, Bird R. Angiotensin converting enzyme and its clinical significance—a review. J Clin Pathol 1983; 36: 938–47
   PubMed Web of Science ®Google Scholar
• Alexander R W, Cooper B, Handin R I. Characterisation of the human platelet α-adrenergic receptor. Correlation of [3H]-dihydroengocryptine binding with aggregation and adenylate cyclase inhibition. J Clin Invest 1978; 61: 1136–46
   PubMed Web of Science ®Google Scholar
• Newman K D, Williams L T, Bishopric N H. Identification of alpha-adrenergic receptors in human platelets by [3H]-dihyroergocryptine binding. J Clin Inves 1978; 61: 395–402
   PubMed Web of Science ®Google Scholar
• Steer M L, Atlas D. Demonstration of human platelet β-adrenergic receptors using 125I-labelled cyanopindolol and 125I-labelled hydroxybenzyl-pindolol. Biochem Biophys Acta 1982; 686: 240–4
   PubMedGoogle Scholar
• Grant J A, Scrutton M C. Novel α2-adrenoceptors primarily responsible for inducing platelet aggregation. Nature (Lond) 1979; 277: 659–61
   PubMedGoogle Scholar
• Hoffman B B, Delean A, Wood C L. Alpha adrenergic receptor subtypes: quantitative assessment by ligand binding. Life Sci 1979; 24: 1739–46
   PubMed Web of Science ®Google Scholar
• Kerry R, Scrutton M C. Platelet β-adrenoceptors. Br J Pharmacol 1983; 79: 681–91
   PubMed Web of Science ®Google Scholar
• Berndt M C, Gregory C, Kabral A. Purification and preliminary characterisation of the glycoprotein Ib complex in the human platelet membrane. Eur J Biochem 1985; 151: 637–49
   PubMedGoogle Scholar
• Du X, Beutier L, Ruan C. Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. Blood 1987; 69: 1524–7
   PubMed Web of Science ®Google Scholar
• Sakariassen K S, Bolhius P A, Sixma J J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636–8
   PubMed Web of Science ®Google Scholar
• Sakariassen K S, Nievelstein P FEM, Coller B S. The role of platelet membrane glycoproteins Ib and IIb–IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681–91
   PubMed Web of Science ®Google Scholar
• Peerschke E IB, Zucker M B, Grant R A. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841–7
   PubMed Web of Science ®Google Scholar
• Shirasawa K, Chandler A B. Fine structure of the bond between platelets in thrombi and platelet aggregates induced by adenosine diphosphate. Am J Pathol 1969; 57: 127–54
   PubMedGoogle Scholar
• Harfinest E J, Packham M A, Kinlough Rathbone R L. Inhibitors of ADP-induced platelet aggregation prevent fibrinogen binding to rabbit platelets and cause rapid deaggregation and dissociation of bound Fibrinogen. J Lab Clin Med 1981; 97: 680–8
   PubMedGoogle Scholar
• Ellen M, Rybak M, Renzulli A. Effect of calcium channel blockers on platelet Gp IIa-IIIa complext as a calcium channel in liposomes: comparison with effects on intact platelet. Thromb Haemost 1992; 67: 131–6
   PubMedGoogle Scholar
• Brass L F. Ca2+ transport across the platelet plasma membrane: a role for glycoprotein IIb-IIIa. J Biol Chem 1985; 260: 2231–6
   PubMedGoogle Scholar
• Yamaguchi A, Yamamoto N, Kitagawa H. Ca2+ influx mediated through the Gp IIb/IIIa complex during platelet activation. FEBBs Lett 1987; 225: 228–32
   PubMed Web of Science ®Google Scholar
• Baenziger N L, Brodie G N, Majerus P W. A thrombin sensitive protein of human platelet membranes. Proc Natl Acad Sci USA 1971; 68: 240–43
   PubMed Web of Science ®Google Scholar
• Houdijk W PM, Sixma J J. Fibronectin in artery subendothelium is important for platelet adhesion. Blood 1985; 65: 598–603
   PubMed Web of Science ®Google Scholar
• Tollefsen D M, Feagler J R, Marjerus P W. The binding of thrombin to the surface of human platelets. J Biol Chem 1974; 249: 2646–51
   PubMedGoogle Scholar
• Martin B M, Wasiewski W W, Fenton J W. Equilibrium binding of thrombin to platelets. Biochemistry 1976; 15: 4886–93
   PubMedGoogle Scholar
• Ball G, Brereton G G, Fulwood M. Effect of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen induced platelet aggregation and on platelet nucleotides including adenosine 3′,5′-cyclic monophosphate. Biochem J 1970; 120: 709–18
   PubMedGoogle Scholar
• Smith J B, Silver M J, Ingerman C M. Prostaglandin D2 inhibits the aggregation of human platelets. Thromb Res 1974; 5: 291–9
   PubMed Web of Science ®Google Scholar
• Cooper B, Ahern D. Characterisation of the platelet PGD2 receptor. Loss of PGD2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest 1979; 64: 586–99
   PubMed Web of Science ®Google Scholar
• Siegl A M, Smith J B, Silver M J. Selection binding sites for [3H] prostacyclin on platelets. J Clin Invest 1979; 63: 215–220
   PubMed Web of Science ®Google Scholar
• MacFarlane D E, Srivastava P C. Mills DCB. 2-methylthioadenosine [B-32P] diphosphate. An agonist and radio-ligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 1983; 71: 421–8
   Google Scholar
• Inaba K, Umeda Y, Urakami M. Platelet vasopressin receptor in essential hypertension. J Hypetens 1988; 6: S389–91, (Suppl 4)
   PubMedGoogle Scholar
• Moore T J, Williams G H. Angiotensin II receptors on human platelets. Circ Res 1982; 51: 314–20
   PubMedGoogle Scholar
• Ding Y A, Kenyon C J, Semple P F. Receptors for angiotensin II on platelets from man. Clin Sci 1984; 66: 725–31
   PubMed Web of Science ®Google Scholar
• Mann J FE, Leidig M, Ritz E. Human angiotensin II receptors are regulated by angiotensin II. Clin Exp Hypertens 1988; 10: 151–68
   Google Scholar
• Ding Y A, MacIntyre D E, Kenyon C J. Angiotensin II effects on platelet function. J Hypertens 1985; 3: S251–3, (Suppl 3)
   Web of Science ®Google Scholar
• Miles L A, Plow E F. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303–11
   PubMedGoogle Scholar
• Miles L A, Plow E F. Receptor mediated binding of the fibrinolytic components. plasminogen and urokinase to peripheral blood cells. Throm Haemost 1987; 58: 936–42
   PubMedGoogle Scholar
• Miles L A, Plow E F. Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 2: 61–71
   Google Scholar
• Tuffin D P. The platelet surface membrane: ultrastructure, receptor binding and function. The platelet in health and disease, C P Page. Blackwell Scientific Publications, Oxford 1991; 48
   Google Scholar
• Frojmovic M, Milton J. Human platelet size shape and related function in health and disease. Physiol Rev 1982; 62: 185–261
   PubMed Web of Science ®Google Scholar
• Thompson C B, Eaton K A, Princiotta S M. Size dependent platelet subpopulations. Relationship of platelet volume to ultrastructure enzymatic activity and function. Br J Haematol 1982; 50: 509–19
   PubMed Web of Science ®Google Scholar
• Knut Lande, Ingrid O S, Kjeldsen S E. Platelet volume, platelet release reaction and platelet response to infused adrenaline are increased in essential hypertension. Acta Med Scand 1986; 714: 129–32, (Suppl 1)
   Google Scholar
• Freedman M, Karpatkin S. Heterogeneity of rabbit platelets. V. Preferential splenic sequestration of megathrombocytes. Br J Haematol 1975; 31: 255–62
   PubMedGoogle Scholar
• Abrahamsen A F. Platelet survival studies in man with special reference to thrombosis and atherosclerosis. Scand J Haematol 1968; 7–53, Suppl 3
   Google Scholar
• Vlachakis N D, Aledort L. Platelet lipid peroxides as determinant of platelet survival and sympathetic stimulation in patients with hypertension. Biochem Med 1979; 21: 94–103
   PubMedGoogle Scholar
• Folts J, Crowell E B, Rowe G G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365–70
   PubMed Web of Science ®Google Scholar
• Spaet T H, Gaynor E, Stemerman M B. Thrombosis atherosclerosis and endothelium. Am Heart J 1974; 87: 661–8
   PubMedGoogle Scholar
• Vlachakis N D, Aledort L. Hypertension and propranolol therapy: effect on blood pressure plasma catecholamines and platelet aggregation. Am J Cardiol 1980; 45: 321–5
   PubMed Web of Science ®Google Scholar
• Cocheri S, Fiorentini P. Platelet adhesiveness and aggregation in hypertensive patients. Acta Med Scand 1971; 273–5, Suppl 525
   PubMedGoogle Scholar
• Nyrop M, Zweifler A J. Editorial review: platelet aggregation in hypertension and the effects of antihypertensive treatment. J Hypertens 1988; 6: 263–9
   PubMed Web of Science ®Google Scholar
• Broddie O E, Stuka N, Demuth V. Alpha-and beta-adrenoreceptors in circulating blood cells of essential hypertensive patients. Increased receptor density and responsiveness. Clin Exp Hypertens [A] 1985; 7: 1135–50
   PubMedGoogle Scholar
• Matsumoto M, Kusunoki M, Uyama O. Platelet aggregation induced by arachidonic acid and thromboxane generation in patient with hypertension or cerebrovascular disease. Prostaglandins Med 1981; 7: 553–62
   PubMedGoogle Scholar
• Matsumoto M, Nukada T, Uyama O. Thromoxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. Thromb Haemost 1980; 44: 16–20
   PubMedGoogle Scholar
• Uyama O, Matsuoto M, Fujisawa A. Plasma concentrations of thromboxane B2 in patients with hypertension or cerebrovascular disease. Prostaglandins Med 1981; 7: 199–207
   PubMedGoogle Scholar
• Hollister A S, Onrot J, Lonce S. Plasma catecholamine modulation of alpha2 adrenoceptor agonist affinity and sensitivity in normotensive and hypertensive human platelets. J Clin Invest 1986; 77: 1416–21
   PubMed Web of Science ®Google Scholar
• Tofler G H, Brezinski D, Schafer A I. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514–8
   PubMed Web of Science ®Google Scholar
• Islim I F, Bareford D, Hart M. Platelet vessel wall interaction in patients with essential hypertension. (Abstract). 15th Scientific Meeting of the International Society of Hypertension, MelbourneAustralia, March, 1994
   Google Scholar
• Wilson J, Orchard M A, Spencer A A. Antihypertensive drugs non-specifically reduce “spontaneous” activation of blood platelets. Thromb Haemost 1989; 62: 776–8
   PubMedGoogle Scholar
• Saniabadi A R, Lowe G DO, Barbenel J C. A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: additional evidence for the role of ADP. Thromb Haemost 1984; 51: 115–8
   PubMed Web of Science ®Google Scholar
• Saninbadi A R, Lowe G DO, Barbenel J C. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225–32
   PubMedGoogle Scholar
• Riozzi A, Heagerty A M, Ollerenshaw J D. Erythrocyte phosphoinosotide metabolism in essential hypertensive patients and their normotensive offspring. Clin Sci 1987; 73: 29–32
   PubMed Web of Science ®Google Scholar
• Bing R F, Heagerty A M, Thurston H. Ion transport in hypertension: are changes in the cell membrane responsible. Clin Sci 1988; 71: 225–30
   Google Scholar
• Ludlam C A, Moore S, Bolton A E. The release of human platelet specific protein meausured by radioimmunoassay. Thromb Res 1975; 6: 543–8
   PubMed Web of Science ®Google Scholar
• Kaplan K, Owen J. Plasma levels of platelet secretory proteins. CRC Crit Rev Oncol Haematol 1986; 5: 235–55
   PubMed Web of Science ®Google Scholar
• Zahavi J, Kakkav V V. B-thromboglobulin–a specific marker of in vivo platelet release reaction. Thromb Haemost 1980; 316: 509–13
   Google Scholar
• Doyle D J, Chesterman C N, Cade J F. Plasma concentration of platelet specific proteins correlated with plasma survival. Blood 1980; 55: 82–4
   PubMed Web of Science ®Google Scholar
• Han P, Turpie A GG, Genton E. Plasma B-thromboglobulin: differentiation between intravascular and extravascular platelet destruction. Blood 1979; 54: 1192–6
   PubMedGoogle Scholar
• Kjeldsen S E, Gjesdal K, Eide I. Increased B-thromboglobulin in essential hypertension: Interaction between arterial plasma adrenaline platelet function and blood lipids. Acta Med Scand 1983; 213: 369–73
   PubMed Web of Science ®Google Scholar
• Zahavi J, Jones N AG, Leyton J. Enhanced in vivo platelet release reaction in old healthy individuals. Thromb Res 1980; 17: 329–36
   PubMedGoogle Scholar
• Hsu C Y, Knapp D R, Hallushka P V. The effects of alpha adrenergic agents on human platelet aggregation. J Pharmacol Exp Ther 1979; 208: 366–70
   PubMed Web of Science ®Google Scholar
• Postono Y U. Essential hypertension as a membrane pathology. Kardiologia 1975; 15: 18–23
   Google Scholar
• Feldman R D, Limbird L E, Nadeau J. Leukocyte β-receptor alterations in hypertensive subjects. J Clin Inves 1984; 73: 648–53
   PubMed Web of Science ®Google Scholar
• Stott D J, Saniabadi A R, Inglis G C. Serotonin and platelet aggregation in patients with essential hypertension compared with a normotensive control group. Drugs 1988; 36: 78–82, (Suppl 1)
   PubMedGoogle Scholar
• Wyse D G. In vitro arterial responses to vasopressin in subjects with a family history of hypertension. J Hypertens 1985; 7: 211–5
   Google Scholar
• Cowley A W, Cushman W C, Quillen E W. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. J Hypertens 1981; 3: 93–100, (Suppl 1)
   Google Scholar
• Erne P, Mihelholzer E, Burgisser F. Measurement of receptor induced changes in intraplatelet free calcium in human platelet. J Recept Res 1984; 4: 587–604
   PubMed Web of Science ®Google Scholar
• Erne P, Burgisser F, Bolli B. Free calcium concentration in platelets closely relates to blood pressure in normal and essential hypertensive subjects. J Hypertens 1984; 6: 1166–9, (Suppl 1)
   Google Scholar
• Erne P, Bolli P, Burgisser F. Correlation of blood platelets with blood pressure. Effect of antihypertensive therapy. N Engl J Med 1984; 310: 1084–6
   PubMed Web of Science ®Google Scholar
• MacIntyre D E, Rink T J. The role of platelet membrane potential in the initiation of platelet aggregation. Thromb Haemost 1982; 47: 22–6
   PubMed Web of Science ®Google Scholar
• Sage S O, Rink T J. Effect of ionic substitution on [Ca2+] rises evoked by thrombin and PAF in human platelets. Eur J Pharmacol 1986; 128: 99–107
   PubMedGoogle Scholar
• Hallam T J, Rink T J. Receptor-mediated Ca2+ entry: diversity of function and mechanism. Trends Pharmacol Sci 1989; 10: 8–10
   PubMedGoogle Scholar
• Mayhaut-Smith M P, Sage S O, Rink T J. Receptor-activated single channels in human platelets. J Biol Chem 1990; 265: 10479–83
   PubMedGoogle Scholar
• Nowycky M C, Fox A P, Tsien R W. Long-opening mode of gating of neuronal calcium channels and its promotion by the dihydropyridine calcium agonist Bay K 8644. Proc Natl Acad Sci USA 1985; 82: 2178–82
   PubMed Web of Science ®Google Scholar
• Amstein R, Fetkovska N, Luscher T F. Age and the platelet serotonin vasoconstrictor axis in essential hypertension. J Cardiovasc Pharmacol 1988; II: 535–40, (Suppl I)
   Google Scholar
• Nowycky M C, Fox A P, Tsien R W. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 1985; 316: 440–3
   PubMed Web of Science ®Google Scholar
• Trautwein W, Kamzeyama M, Hescheler J. Cardiac calcium channels and their transmitter modulation. Membrane control of cellular activity, H L Luttgan. Gustav-Fischer-Verlag, Stuttgart 1986; 162–82
   Google Scholar
• Trautwein W, Cavalie A, Flockerzi V. Modulation of calcium channel function by phosphorylation in guinea pig ventricular cells and phospholipid bilayer membranes. Circ Res 1987; 61: 117–23, (Suppl I)
   PubMedGoogle Scholar
• Tsien R W, Bean B P, Hess P. Calcium channels: mechanisms of β-adrenergic modulation and ion permeation. Cold Spring Harbor Symposia on quantitative biology 1983; 157: 201–12
   Google Scholar
• Resink T J, Dimitrov D, Zschauer A. Platelet calcium linked abnormalities in essential hypertension. Ann NY Acad Sci 1986; 488: 252–65
   PubMedGoogle Scholar
• Postnov Y V, Orlov S N. Cell membrane alterations as a source of primary hypertension. J Hypertens 1984; 1: 14
   Google Scholar
• Irine R F, Moore R M. Microinjection of inositol-1,3,4,5-tetrakisophosphate activates sea urchin eggs by a mechanism dependent on external Ca2+. Biochem J 1986; 240: 914–20
   Google Scholar
• Putney J W. A model for receptor-regulated calcium entry. Cell Calcium 1986; 7: 1–12
   PubMed Web of Science ®Google Scholar
• Dimitrav V, Resink T J, Muller F B. Altered platelet phosphoinositol metabolism in essential hypertension. J Hypertension 1986; 4: S346–8, (Suppl 6)
   Google Scholar
• Gorman R R. Modulation of platelet function by prostacyclin and thromboxane A2. Fed Proc 1979; 32: 83–8
   Google Scholar
• Haslam R J, Davidson M ML, Knight D E. GTP not cyclic GMP enhances secretion from permeabilised platelets. Nature 1985; 313: 821–2
   PubMedGoogle Scholar
• Haslam R J, Williams K A, Davidson M ML. Receptor-effect or coupling in platelets: roles of guanine nucleotids. Mechanisms of stimulus–response coupling in platelets, J Westwick, M F Scully, D E McIntyre, V Kakkar. Plenum Press, New York 1985; 265–80
   Google Scholar
• Marcus A J, Ullman H L, Safier L B. Lipid composition of subcellular particles of human platelets. J Lipid Res 1969; 10: 108–14
   PubMed Web of Science ®Google Scholar
• Nayler W G. Calcium antagonist binding sites: their density, size, structure and development. Calcium antagonists, W D Nayler. Academic Press, Oxford 1988; 96
   Google Scholar
• Winther K, Knudsen J B, Gormsen J. Effect of metoprolol and propronolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986; 29: 561–4
   PubMedGoogle Scholar
• Winther K, Trap-Jensen J. Effects of three beta blockers with different pharmacodynamic properties on platelet aggregation platelet and plasma cyclic AMP. Eur J Clin Pharmacol 1988; 35: 17–20
   PubMedGoogle Scholar
• Cantaro S, Calo L, Vianello G P. Platelet calmodulin and phospholipase A2 activity in essential hypertension. Regul Pept 1985; 144–7, Suppl 4
   Google Scholar
• Resink T J, Tkachok P, Erne P. Altered platelet membrane Ca2+-ATPase in patients with established essential hypertension. In: 2nd Eur. meeting hypertens, Milan, Italy 1985; R347
   Google Scholar
• Resink T J, Tkachok V A, Erne P. Platelet membrane calmodulin-stimulation Ca2+-AtPase: altered activity in essential hypertension. J Hypertens 1986; 8: 159–66
   Google Scholar
• Ahtee L, Pentikainen P J, Pentikainen M K. 5-hydroxytryptamine in the blood platelets of cirrhotic and hypertensive patietns. Experientia 1974; 30: 1328–9
   PubMedGoogle Scholar
• Kamal L A, Raisman R, Meyer P. Reduced Vmax of 3-H serotonin uptake but unchanged 3H-imipramine binding in the platelets of untreated hypertensive subjects. Life Sci 1984; 34: 2083–8
   PubMed Web of Science ®Google Scholar
• Baudouin-Legros, Le Quan-Bui K M, Guicheney P. Platelet serotonin and abnormal tissue perfusion. Serotonin and the cardiovascular system, P M Vanhoutte. Raven Press, New York 1985; 155–64
   Google Scholar
• Shattil S J, Anaya-Gaklindo R, Bennett J. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636–42
   PubMed Web of Science ®Google Scholar
• Chandra M, Chandra N. Serotonergic mechanisms in hypertension (Review). Int J Cardiol 1993; 42: 189–96
   PubMed Web of Science ®Google Scholar
• Feinberg H, Sandler W C, Scorer M. Movement of Na2+ into human platelets induced by ADP. Biochem Biophys Acta 1977; 470: 317–24
   PubMedGoogle Scholar
• Horne W C, Norman N E, Schwartz D B. Changes in cytoplasmic pH and in membrane potential in thrombin-stimulated platelets. Eur J Biochem 1981; 120: 295–302
   PubMedGoogle Scholar
• Horne W C, Simon E R. Effects of amiloride on the response of human platelets to bovine alpha thrombin. Thromb Res 1978; 13: 599–607
   PubMedGoogle Scholar
• Mattaison I, Mattaison B, Hood B. The efflux rate of norepinephrine from platelets and its relation to blood pressure. Life Sci 1979; 24: 2265–72
   PubMedGoogle Scholar
• Mattaison I, Mattaison B, Hood B. Uptake and efflux of noradrenaline from platelets; a model system for neurogenic mechanisms in essential hypertension. Clin Sci 1979; 57: 225S–7
   Google Scholar
• Mattaison I, Hood B. Efflux of noradrenaline from platelets in normotensive members of hypertensive families. Clin Sci 1982; 62: 151–5
   Google Scholar
• Le Grand C, Duberand V, Meyer P. Correlation between noradrenaline fluxes metabolism and compartmentalisation in human platelets. Thromb Haemost 1982; 48: 62–6
   PubMedGoogle Scholar
• Kuchel O, Buu N T, Fontaine P. Free and conjugated plasma catecholamine in hypertensive patients with and without phaeochromocytoma. J Hypertens 1980; 2: 177–86
   Google Scholar
• Kuchel O, Buu N T, Hamet V. Catecholamine sulphates and plaelet phenosulphotransferase activity in essential hypertension. J Lab Clin Med 1984; 104: 238–44
   PubMed Web of Science ®Google Scholar
• Patrassi G M, Fallo F, Martinelli S. The contact phase of blood coagulation and renin activation in essential hypertension before and after captopril. Eur Heart J 1984; 5: 561–7
   PubMedGoogle Scholar
• Ettanger M M, MacCarthy E P, Glass-Greenwalt P. Abnormalities of fibrinolysis in essential hypertension. J Hypertens 1984; 2: 175–8, (Suppl 3)
   Google Scholar
• Patrassi G M, Fallo F, Santarossa A. Clotting changes in borderline hypertension. J Hum Hypertens 1987; 1: 101–3
   PubMed Web of Science ®Google Scholar
• Islim I F, Bareford D, Beevers D G. New concepts in platelet function in essential hypertension (Abstract). Comm of the First Platelet Res Conf, London, December, 1991
   Google Scholar
• Islim I F, Bareford D, Hart M. A primary abnormality of platelet function in hypertension; improvement with ACE inhibition (abstract). 2nd International Joint Workshop: International Union of Angiology and European Cardiac Society, Monte Carlo, January, 1993
   Google Scholar
• Islim I F, Bareford D, Hart M. A primary abnormality of platelet function in hypertension; improvement with ACE inhibition. JACC 1993; 21: 257A
   Google Scholar
• Cook N S, Ubben O. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990; 11: 444–51
   PubMed Web of Science ®Google Scholar
• Rainer C H, Kawaniski D T, Chandraratna N. Changes in blood rheology in patients with stable angina pectoris as a result of coronary artery disease. Circulation 1987; 76: 15–20
   PubMedGoogle Scholar
• Stone M C, Thorp J M. Plasma fibrinogen–a major cardiovascular risk factor. J R Coll Gen Pract 1985; 35: 565–9
   PubMedGoogle Scholar
• Kannel W B, D'Agostino R B, Belanger A J. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183–6
   PubMed Web of Science ®Google Scholar
• Balleisen L, Schulte H, Assmann G. Coagulation factors and the progress of coronary heart disease. Lancet 1987; i: 462
   Google Scholar
• Yarnell J WG, Baker J A, Sweetman P M. Fibrinogen visosity and white blood cell count are major risk factors for ischaemic heart disease. Circulation 1991; 83: 836–44
   PubMed Web of Science ®Google Scholar
• Ernest E. Fibrinogen; an independent risk factor for cardiovascular disease. BMJ 1991; 303: 596–7
   PubMedGoogle Scholar
• Fuster V, Bowie E JW, Lewis J C. Resistence to atherosclerosis in pigs with von Willebrand's disease. J Clin Invest 1978; 61: 722–30
   PubMed Web of Science ®Google Scholar
• Bowie E JW, Fuster V, Fass D N. The role of von Willebrand factor in platelet vessel interaction including a discussion of resistence to atherosclerosis in pigs with von Willebrand's disease. Philos Trans R Soc Lond 1981; B294: 267–79
   Google Scholar
• Lufkin E G, Fass D N, O'Fallon W M. Increased von Willebrand factor in diabetes mellitus. Metabolism 1979; 28: 63–6
   PubMed Web of Science ®Google Scholar
• Boneau B, Durand D, Counillon F. Increased levels of factor VIII complex in severe arterial disease. Thromb Haemost 1978; 7: 332–8
   Google Scholar
• Boneau B, Abbal M, Plante J. Factor VIII complex and endothelial damage. Lancet 1975; i: 1430
   Google Scholar
• Silverstein E, Friedland J. Serum converting enzyme in sarcoidosis and other diseases. Lancet 1979; i: 382–3
   Google Scholar
• Katz P, Fauci A S, Yeager H, Jr. Serum angiotensin-converting enzyme and lysozyme in granulomatous disease of unknown cause. Ann Intern Med 1981; 94: 359–60
   PubMedGoogle Scholar
• Lieberman J, Saster A. Serum angiotensin converting enzyme elevation in diabetes mellitus. Ann Intern Med 1980; 93: 825–6
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Schwartzer G H, Kuzmits R. Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type state of metabolic control and occurence of diabetic vascular disease. J Clin Pathol 1984; 37: 307–12
   PubMedGoogle Scholar
• Yotsumoto H, Imai Y, Kuzuja N. Increased levels of serum angiotensin–converting enzyme activity in hyperthyroidism. Ann Intern Med 1982; 96: 326–8
   PubMed Web of Science ®Google Scholar
• Browskey S A, Lieberman S, Strome S. Elevation of serum angiotensin converting enzyme level. Occurrence in alcoholic liver disease. Arch Intern Med 1982; 142: 893–5
   PubMedGoogle Scholar
• Niarchos A P, Resink L M, Weinstein D L. Angiotensin I converting enzyme activity in hypertension. Relation to blood pressure renin-sodium profiles and antihypertensive therapy. Am J Med 1985; 79: 435–44
   PubMed Web of Science ®Google Scholar
• Schweisfurth H, Kment A, Dahlheim H. Elevated angiotensin I-converting enzyme (ACE) in patients with essential hypertension. Klin Wochenschr 1982; 60: 49–50
   PubMedGoogle Scholar
• Overlack A, Higuchi M, Koloch R. Converting enzyme activity and essential hypertension. Klin Wochensschr 1983; 61: 377–8
   PubMedGoogle Scholar
• Muumeci V, Cardillo C, Baroni S. Plasma markers of endothelial cells and platelet activation following handgrip in normals and hypertensive patients. J Clin Hypertens 1987; 3: 487–99
   PubMedGoogle Scholar
• Panza J A, Casino P R, Kilcoyne C M, Quyyumi A A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468–74
   PubMed Web of Science ®Google Scholar
• Mahta J L, Lopez L M, Chen L, Cox O E. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 1994; 74: 901–5
   PubMedGoogle Scholar
• Zahavi J, Kakkar V V. B-thromboglobulin–a specific marker of in vivo platelet release reaction. Thromb Haemost 1980; 44: 23–9
   PubMed Web of Science ®Google Scholar
• Ludlam C A. Evidence for the platelet specificity of B-thromboglobulin studies and its plasma concentration in healthy individuals. Br J Haematol 1979; 41: 271–8
   PubMed Web of Science ®Google Scholar
• Ludlam C A, Cash J D. B-thromboglobulin: a new tool for the diagnosis of hypercoagulability. Haemostasis and thrombosis. Proceedings of serono symposium, G G Neri Serniri, C RM Prentice, London 1979; 15: 159–67
   Google Scholar
• Zahavi J, Jones N AG, Leyton J. Enhanced in vivo platelet release reaction in old healthy individuals. Thromb Res 1980; 17: 329–36
   PubMedGoogle Scholar
• Gordon T, Castelli W P, Hjortland M C. High density lipoproteins as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707–14
   PubMed Web of Science ®Google Scholar
• Canadian Stroke Study Group. A randomised trial of aspirin and sulphinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53–9
   PubMedGoogle Scholar
• Veterans Administrative Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA 1967; 202: 1028–34
   PubMedGoogle Scholar
• Fuster V, Chesebro J H, Fry R L. Platelet survival and the development of coronary disease in young adults. Effects of cigarette smoking strong family history and medical therapy. Circulation 1981; 63: 546–51
   PubMed Web of Science ®Google Scholar
• Packham M A. Methods for detection of hypersensitive platelets. Thromb Haemost 1964; 2: 34–41
   Google Scholar
• Ozge A H, Mustard J F. The effect of repeated adrenaline injection on blood coagulation and platelet economy in rabbits. Proceedings of the Ninth Congress of the International Society of Haematology 1964; 2: 34–41
   Google Scholar
• Gjesdal K, Kjeldsen S E, Lande K. Blood platelet release correlates with serum lipids in 50 year old men with essential hypertension. Acta Med Scand 1986; 714: 125–8
   Google Scholar
• Leren P, Askevold E-M, Foss O P. The Oslo Study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand 1975, Suppl. 558
   Google Scholar
• Carvalho A CA, Colman R W, Lees R S. Platelet function in hyperlipoproteinaemia. N Engl J Med 1974; 290: 434–8
   PubMed Web of Science ®Google Scholar
• Holme I, Helgeland A, Hjermann I. Four and two-thirds years incidence of coronary heart disease in middle aged men: The Oslo study. Am J Epidemiol 1980; 112: 149–60
   PubMed Web of Science ®Google Scholar
• Catalano M, Belletti S, Russo U. Platelet activation indices and apolipoproteins in hypertensive patients. J. Hum Hyper 1988; 2: 195–7
   PubMedGoogle Scholar
• Stuart M J, Gerrard J M, White J G. Effect of cholesterol on the production of thromboxane B2 by platelets in vitro. N Engl J Med 1990; 302: 6–10
   Google Scholar
• Jakubowski J A, Ardlie N G, Nestel P J. The effect of hypercholesterolaemia on the lipid composition and ability of human platelets to accumulate cyclic AMP. Prostaglandins Med 1980; 5: 457–67
   PubMedGoogle Scholar
• Kannel W B, Castelli W P, Gordon T. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1–12
   PubMed Web of Science ®Google Scholar
• Burrows A W, Chaven S I, Hockaday T DR. Plasma B-thromboglobulin concentration in diabetes mellitus. Lancet 1978; i: 235
   Google Scholar
• Kwaan H C, Colwell J A, Cruz S. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236–46
   PubMed Web of Science ®Google Scholar
• Preston F E, Ward J D, Marcola B H. Elevated B-thrombogloulin levels and circulating platelet aggregates in diabetic micoangiopathey. Lancet 1978; i: 238
   Google Scholar
• O'Malley B C, Timbley W R, Ward J D. Platelet abnormalities in diabetic peripheral neuopathy. Lancet 1975; ii: 1274–6
   Google Scholar
• Heath H, Brigden W D, Canever J V. Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 1971; 7: 308–15
   PubMed Web of Science ®Google Scholar
• Torsellini A, Becucci A, Citi S. Effects of pressure excursions on human platelets. In vitro studies on beta thromboglobulin (BTG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation. Haematologica 1982; 67: 860–6
   PubMedGoogle Scholar
• Nordoy A, Rorvik T O. Some effects of adrenaline on rat platelets in vitro and in vivo. Scand J Clin Lab Invest 1965; 115–8, Suppl 84
   Google Scholar
• Hoak J C, Spector A A, Fry G L. Effect of free fatty acids on ADP-induced platelet aggregation. Nature 1970; 228: 1330–2
   PubMedGoogle Scholar
• Biondi M L, Agostoni A, Marasaini B. Serotonin levels in hypertension. J Hypertens 1986; 4: S39–41, (Suppl 1)
   PubMedGoogle Scholar
• Cuicheney P, Deynck M A, Cloix J F. Platelet 5-HT content and uptake in essential hypertension: role of endogenous digitalis-like factors and plasma cholesterol. J Hypertens 1988; 6: 873–9
   PubMedGoogle Scholar
• Lindner A, Kenny M, Meacham A J. Effects of a circulating factor in patients with essential hypertension on intracellular free calcium in normal platelets. N Engl J Med 1987; 316: 509–13
   PubMed Web of Science ®Google Scholar
• Shattil S J, Cooper R H. Membrane viscosity and human platelet function. Biochemistry 1976; 15: 4832–7
   PubMed Web of Science ®Google Scholar
• Stimpel M, Neyses L, Locher R. High density lipoproteins–modulators of calcium channel. J Hypertens 1985; 3: S49–51, (Suppl 3)
   Google Scholar
• Locher R, Knorr M, Edmonds D. Influence of cholesterol in intra-cellular free calcium concentration in human platelets. J Hypertens 1968; 4: S358–60, (Suppl 5)
   Google Scholar
• Letcher R L, Chien S, Pickering T G. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med 1981; 70: 1195–202
   PubMed Web of Science ®Google Scholar
• Vlachakis N, Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atheroslerosis 1979; 32: 451–60
   PubMed Web of Science ®Google Scholar